Dr Lal Pathlabs Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹703Cr
- +16.6% YoY
- +6.5% QoQ
- Net profit
- ₹132Cr
- −15.4% YoY
- +45.1% QoQ
- Margin
- 27%
- −1 pp YoY
- 0 pp QoQ
Guidance rank: #24 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery.
From Dr Lal Pathlabs's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually).
- Patient volume growth is expected to improve gradually, supported by expansion of labs and collection networks.
- Recent quarter showed an 8.2% volume growth, but annualized growth (~5.3%) is a better indicator.
- Growth is broad-based across regions, with sustained double-digit growth in Delhi NCR and improving growth in Suburban business.
- Expansion in Tier 3 and Tier 4 geographies contributing positively without diluting realizations.
- Increased focus on health packages and specialized testing, including the preventive healthcare brand Swasthfit (27% revenue contribution).
- New labs and network additions (12-15 labs planned next year) will support volume growth.
2 more points from Dr Lal Pathlabs's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Dr Lal Pathlabs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY27 capex guidance is Rs. 100 crore - Rs. 120 crore.
- Capex includes both maintenance and growth investments.
- Growth capex planned for opening 12 to 15 new labs next year (14 labs added in current year).
- Investments in a precision diagnostic lab with high-end complex testing equipment.
- Incorporation of a subsidiary in Dubai as part of international expansion, considering both organic and inorganic opportunities including potential M&A in Middle East.
- Some investments planned in radiology centers – slow and calibrated growth approach on radiology expansion, including integrated high-end radiology centers in Delhi NCR and possibly Tier 2 towns.
2 more points from Dr Lal Pathlabs's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Lal Pathlabs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Dr Lal Pathlabs's call on order book
Create a free account to keep reading this call
Dr Lal Pathlabs — Quarterly revenue & net profit
Dr Lal Pathlabs Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 703 | 603 | +16.6% | 660 | +6.5% |
| Operating profit (EBITDA) | 187 | 169 | +10.7% | 179 | +4.5% |
| Operating margin | 27% | 28% | -1 pp | 27% | 0 pp |
| Profit before tax | 160 | 153 | +4.6% | 124 | +29% |
| Net profit (PAT) | 132 | 156 | -15.4% | 91 | +45.1% |
| EPS (₹) | 7.84 | 9.26 | -15.3% | 5.40 | +45.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹874 Cr, net profit ₹194 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Lal Pathlabs's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Dr Lal Pathlabs and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Lal Pathlabs Q4 FY26 results?
Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery.
What is Dr Lal Pathlabs share price analysis?
Dr Lal Pathlabs currently shows a neutral. The stock trades at a P/E of 56.5 with a market cap of ₹31,794 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs planning capital expenditure?
FY27 capex guidance is Rs. 100 crore - Rs. 120 crore.
Keep Dr Lal Pathlabs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
